Why Medicines Run Short: The Journey Most Patients Never See

A box of paracetamol in a bathroom cabinet. A bag of saline hanging beside a hospital bed. Both have already crossed borders, changed hands, and passed a dozen inspections before they reached the people who need them. This is where that journey runs — and where it breaks.

A journey most patients never see

Every medicine begins as two separate ingredients: the active substance that does the clinical work, and the excipients — the fillers, coatings, stabilisers and solvents — that turn a compound into a tablet, capsule or injectable. These are rarely made in the same place, or even the same country. A single medicine can draw its active substance from one manufacturer, its excipients from another, and its final packaging from a third — each a separate site, a separate regulator, a separate point where something can go wrong.

From two ingredients to one medicine

Combining active substance and excipient into a finished dose — a tablet pressed, a vial filled, an injection prepared — is only the midpoint of the chain. Before a batch can leave the factory, it is tested against the specifications lodged with the regulator: purity, potency, sterility, stability. This is where most shortages begin. A failed stability result, a contamination flag, or a deviation from the validated process can place an entire batch — sometimes an entire month of production — on hold pending investigation. Global supply doesn't switch to a substitute; it stops, until the batch clears or is discarded.

Packaged twice before it reaches a shelf

A finished dose still isn't something a pharmacist can dispense. It's first sealed into primary packaging — a blister strip, an ampoule, a vial — then packed with its patient information leaflet into a secondary carton approved for its destination market. Both steps depend on their own supply chains: printed foil, medical-grade glass, approved cartons, leaflets compliant with the regulator in each market they're bound for. A shortage of a single packaging component can strand a fully manufactured medicine in a warehouse — finished, but not yet fit to sell.

The signature that releases the batch

Before a single unit can be sold anywhere, a qualified person at a licensed facility must formally certify the batch — confirming that manufacturing, testing and packaging all meet the approved specification. This batch release step is deliberately singular: one authorised signature, one facility, no shortcuts. It is also a bottleneck. A documentation query, a change of release site, or a question raised by the regulator can hold a fully compliant medicine at the factory gate for weeks, while patients elsewhere are already out of stock.

Wholesaler to ward: the last mile

Only once a batch is released does it move — through a wholesaler, into a pharmacy or hospital pharmacy, and finally to the patient. This last leg draws the most attention, because it's the one people can see: empty shelves, back-ordered lines, a pharmacist explaining there is nothing left to dispense. But the last mile rarely causes a shortage. It delivers the consequences of whatever happened upstream, months or occasionally years earlier.

A single medicine can pass through eight or more licensed facilities, in as many countries, before it reaches a patient. It only takes one of them to break the chain.

Why this chain is so fragile

Generic and off-patent medicines — the ones most exposed to shortage — carry the thinnest margins, which means few manufacturers hold spare capacity. Active substance production is concentrated in a small number of facilities worldwide, so a single plant closure, export restriction or logistics disruption can affect the global supply of a medicine overnight, regardless of demand in any one country. Layer in packaging component scarcity, quality holds and batch release queues, and it becomes clear why a shortage notice rarely has one cause — and rarely has a quick fix.

How ProPG bridges the gap

When a medicine becomes unavailable through routine channels, the chain above doesn't reset itself — someone has to search it, link by link, for an alternative that is safe, compliant and real. That is the work of ProPG's Medicines for Shortages service. We hold direct relationships with licensed suppliers across 30+ countries, source through TGA-approved pathways including Section 19A and the Special Access Scheme, and move product GDP-compliant from source to bedside. Our CheckMed platform tracks emerging shortage risk before it reaches a hospital shelf, and our Jemstar network in Poland extends our reach into EU warehousing and logistics when a solution sits offshore.

30+ countries in our supplier network. Three licensed pharmaceutical sites — Melbourne, Hamburg, Warsaw. One promise: no patient is left without options.

We listen. We find. We deliver.

Facing a shortage you can't resolve through usual channels? Talk to ProPG's Medicines for Shortages team at propg.com.au.